NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug

All NewsMarch 16, 2026

The FDA signals its willingness to review NRx Pharmaceuticals’ NRX-100 NDA, boosting optimism around its depression treatment.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent